1645 related articles for article (PubMed ID: 27426430)
41. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
42. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
43. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.
Daly ME; Monjazeb AM; Kelly K
J Thorac Oncol; 2015 Dec; 10(12):1685-93. PubMed ID: 26484629
[TBL] [Abstract][Full Text] [Related]
44. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
Giri A; Walia SS; Gajra A
Rev Recent Clin Trials; 2016; 11(4):297-305. PubMed ID: 27457350
[TBL] [Abstract][Full Text] [Related]
45. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Califano R; Kerr K; Morgan RD; Lo Russo G; Garassino M; Morgillo F; Rossi A
Curr Oncol Rep; 2016 Sep; 18(9):59. PubMed ID: 27484062
[TBL] [Abstract][Full Text] [Related]
46. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
47. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
48. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
49. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint inhibitors in lung cancer: current status and future directions.
Fan Y; Mao W
Chin Clin Oncol; 2017 Apr; 6(2):17. PubMed ID: 28482670
[TBL] [Abstract][Full Text] [Related]
51. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Zhou F; Qiao M; Zhou C
Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
[TBL] [Abstract][Full Text] [Related]
52. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
53. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
54. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
[TBL] [Abstract][Full Text] [Related]
55. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
Provencio M; Carcereny E; Artal Á
Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517
[TBL] [Abstract][Full Text] [Related]
56. Current status of immunotherapy for non-small-cell lung cancer.
Imbimbo M; Lo Russo G; Blackhall F
Tumori; 2016 Aug; 102(4):337-51. PubMed ID: 27443896
[TBL] [Abstract][Full Text] [Related]
57. The estrogen pathway as a modulator of response to immunotherapy.
Velez MA; Burns TF; Stabile LP
Immunotherapy; 2019 Sep; 11(13):1161-1176. PubMed ID: 31361169
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
[TBL] [Abstract][Full Text] [Related]
59. Nivolumab for treating non-small cell lung cancer.
Guibert N; Mazières J
Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
[TBL] [Abstract][Full Text] [Related]
60. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
